One hundred patients hospitalized and in need of oxygen treatment due to Covid-19 should be randomized and 50% treated with 200 ml convalescent plasma x 3 and 50% given ordinary treatment. Primary outcome is number of days the patients need oxygen within 28 days from inclusion. Secondary outcome is number of days in hospital, number of days in respirator and mortality. Side effects of treatment is monitored.
Subjects with previous verified COVID-19 are asked to donate plasma 14 days or later after
recovery. IgG antibodies against Covid-19 are measured and only subjects with high titers are
accepted. Plasmaphereses is done and up to 600 ml plasma is drawn and aliquoted in 200 ml
portions.
Patients with acute respiratory symptoms, verified Covid-19, hospitalized and in need of
oxygen treatment are asked to participate in the study. The patients are randomized 50/50 to
get either convalescent plasma or routine treatment without plasma. The patients randomized
to get plasma will have infusion of 200 ml blood group compatible convalescent plasma daily
during three days from different donors.
The clinical course will be carefully monitored and days with oxygen requirement will be
compared between the groups. Secondary clinical outcomes as mortality, need of assisted
ventilation, total days in hospital and side effects to treatment will be observed.
Biological: Convalescent plasma
Plasma donated from patients recovered from Covid-19 and having high titres of antibodies
Inclusion Criteria:
- Verified diagnosis of Covid-19
- <94% oxygen saturation
- willingness to participate
- ability to sign informed consent
Exclusion Criteria:
- unability to understand information and sign informed consent
- immunosuppressed patient
Skåne University Hospital
Lund, Sweden
Investigator: Mona Landin-Olsson, MD, Prof
Contact: +4646171000
mona.landin-olsson@med.lu.se
Magnus Rasmussen, MD, Prof
+4646171000
magnus.rasmussen@med.lu.se
Mona Landin-Olsson, MD, Prof
+4646171000 - 71452
mona.landin-olsson@med.lu.se